NH TherAguix announces the arrival of Dr. Olivier de Beaumont as Chief Medical Officer

Meylan, France, September 9th, 2022

NH TherAguix (“NHT”), a French clinical biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, announces today the arrival of Dr. Olivier de Beaumont as Chief Medical Officer from September 22.
Oncology specialist, Olivier de Beaumont will bring his expertise to NHT clinical development. Especially, based on its preliminary very encouraging Phase 2 results, NHT is deepening its registration strategy. Olivier de Beaumont succeeds Dr. Markus Loeffler who has been on this mission for 3 years. Olivier de Beaumont will be in charge of the company’s clinical development strategy, its validation by regulatory authorities and its operational implementation, with a view to register the candidate drug AGuIX®. He joins the Management Committee of NHT with Géraldine Le Duc (CEO) and Hervé Brailly (Chairman).

Before joining NHT, Olivier de Beaumont served as Chief Medical Officer at ONXEO, where he was in charge of AsiDNA® for 6 years, leading early clinical development program from First in Man to successful Phase 2 proof of concept studies. Olivier de Beaumont previously led several clinical development programs, medical affairs and drug safety, as Senior Vice President at Stallergenes Greer, as Director of Business Development for Europe at Quintiles and as global late phase and pharmacoeconomic programs for Oncology at Aventis.
Olivier de Beaumont is a medical doctor and holds an MBA from ESCP and a Master’s in Public Health and Health Economics.

LEARN MORE